Clinical Trial Update: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MRG002 in HER2-positive biliary tract cancer (advanced/metastatic, unresectable).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced or Metastatic Biliary Tract Cancer | Phase 2 | Status: UNKNOWN